Table 3. Frequency of cardiac events between 2017–2021 in 5-year survivors of childhood cancer (diagnoses 1991–2011) stratified by follow-up duration and primary cancer diagnosis and in a matched*1comparison group.
| Follow-up period*2 | Frequency of cardiac events N (%) *3 *4 | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 5 to < 10 years | 10 to < 20 years | 20 to < 30 years | All | |||||||||
| Median age at 1 January 2017 | 13.5 (IQR = 8) | 20.5 (IQR = 8) | 28.5 (IQR = 8) | 21.5 (IQR = 11) | ||||||||
| Childhood cancer type | Survivors | Comparison group | PR
[95% Cl] |
Survivors | Comparison group | PR
[95% Cl] |
Survivors | Comparison group | PR
[95% Cl] |
Survivors | Comparison group | PR
[95% Cl] |
| Lymphoid leukemia | 85
(9.2) |
56
(2.0) |
4.6
[3.3; 6.3] |
98
(5.9) |
127
(2.6) |
2.3
[1.8; 3.0] |
53
(6.0) |
88
(3.3) |
1.8
[1.3; 2.5] |
236
(6.8) |
271
(2.6) |
2.6
[2.2; 3.1] |
| Acute myeloid leukemia | 13
(9.2) |
8
(1.9) |
4.9
[2.1; 11.5] |
17
(7.5) |
16
(2.3) |
3.2
[1.6; 6.2] |
9
(8.2) |
14
(4.2) |
1.9
[0.9; 4.3] |
39
(8.2) |
38
(2.6) |
3.1
[2.0; 4.8] |
| Hodgkin lymphoma | 9
(4.7) |
11
(1.9) |
2.5
[1.0; 5.8] |
17
(6.1) |
27
(3.2) |
1.8
[1.0; 3.4] |
25
(12.8) |
35
(6.0) |
2.1
[1.3; 3.5] |
51
(7.6) |
73
(3.6) |
2.1
[1.5; 3.0] |
| Non-Hodgkin lymphoma | 13
(5.5) |
13
(18) |
3.0
[1.4; 6.4] |
24
(6.6) |
25
(2.3) |
2.9
[1.7; 5.0] |
12
(5.1) |
22
(3.2) |
1.6
[0.8; 3.3] |
49
(5.9) |
60
(2.4) |
2.5
[1.7; 3.5] |
| CNS tumor | 29
(3.7) |
54
(2.3) |
1.6
[1.0; 2.5] |
56
(4.8) |
91
(2.6) |
1.9
[1.3; 2.6] |
20
(4.2) |
44
(3.1) |
1.4
[0.8; 2.3] |
105
(4.4) |
189
(2.6) |
1.7
[1.3; 2.1] |
| Neuroblastoma | 17
(8.8) |
4
(0.7) |
12.8
[4.3; 37.4] |
16
(3.9) |
21
(1.7) |
2.3
[1.2; 4.3] |
8
(4.3) |
13
(2.3) |
1.8
[0.8; 4.4] |
41
(5.2) |
38
(16) |
3.2
[2.1; 5.0] |
| Renal tumor | 22
(11.6) |
11
(1.9) |
6.0
[3.0; 12.1] |
23
(6.0) |
18
(16) |
3.8
[2.1; 7.0] |
21
(113) |
18
(3.2) |
3.5
[1.9; 6.4] |
66
(8.7) |
47
(2.1) |
4.2
[2.9; 6.1] |
| Bone tumor | 16
(12.4) |
5
(13) |
9.6
[3.6; 25.7] |
27
(13.6) |
16
(2.7) |
5.1
[2.8; 9.2] |
15
(10.8) |
21
(5.0) |
2.1
[1.1; 4.0] |
58
(12.4) |
42
(3.0) |
4.1
[2.8; 6.1] |
| Soft tissue sarcoma | 1
(8.8) |
10
(18) |
4.8
[2.2; 10.4] |
32
(10.8) |
21
(2.4) |
4.6
[2.7; 7.8] |
11
(7.8) |
14
(3.3) |
2.4
[1.1; 5.1] |
59
(9.5) |
45
(2.4) |
3.9
[2.7; 5.7] |
| Intracranial germ cell tumor | 0 | 0 | / | 1
(16) |
12
(6.5) |
0.3
[0.0; 1.9] |
3
(10.7) |
3
(3.6) |
3.0
[0.6; 14.0] |
4
(3.3) |
15
(4.2) |
0.8
[0.3; 2.4] |
| Other | 16
(3.7) |
25
(2.0) |
1.9
[1.0; 3.6] |
23
(3.7) |
35
(1.9) |
2.0
[1.2; 3.3] |
10
(4.5) |
16
(2.4) |
1.9
[0.9; 4.1] |
49
(3.9) |
76
(2.0) |
1.9
[1.4; 2.8] |
Matching criteria: age, sex, region of residence, duration of insurance
Follow-up period: time from cancer diagnosis until 1 January 2017
Defined according to the International Classification of Diseases (ICD-10): congestive heart failure/cardiomyopathy (I42), valvular heart disease (I34-I39), cardiac arrhythmias (I47-I49), pericardial disease (131), coronary heart disease/ ischemic heart disease (I20-I25), cardiac insufficiency (I50)
At least one recorded cardiac diagnosis in at least two different quarters during the SHI insurance period 2017–2021
Cl, Confidence interval; CNS, central nervous system; IQR, interquartile range; N, absolute numbers; PR, prevalence ratio; SHI, statutory health insurance carrier; Survivors, 5-year survivors after childhood cancer